C. Labandeira

发表

Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19

R. Franco, Gemma Navarro, A. Rodriguez-Perez, 2021, Clinical science.

Insulin-Like Growth Factor-1 and Neuroinflammation

A. Rodriguez-Perez, J. Labandeira-Garcia, C. Labandeira, 2017, Front. Aging Neurosci..

Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease

J. Kulisevsky, P. Martínez-Martín, M. Kurtis, 2020, European journal of neurology.

Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2022, Biomedicines.

Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report

C. Labandeira, J. García Mata, M. Salgado Fernández, 2020, Case Reports in Oncology.

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

I. Abdulkader, C. Rolfo, C. Labandeira, 2019, Front. Oncol..

Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: Focus on glucagon-like peptide-1 receptor agonists

A. Rodriguez-Perez, C. Labandeira, A. Muñoz, 2021, Frontiers in Neuroendocrinology.

Falls Predict Acute Hospitalization in Parkinson’s Disease

J. Kulisevsky, P. Martínez-Martín, P. Pástor, 2021, Journal of Parkinson's disease.

High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

I. Parees, J. Kulisevsky, P. Martínez-Martín, 2019, Journal of Neural Transmission.

Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing

A. Rodriguez-Perez, C. Labandeira, D. Arias Ron, 2022, Neural regeneration research.

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2022, npj Parkinson's Disease.

Interactions between ibuprofen, ACE2, renin‐angiotensin system, and spike protein in the lung. Implications for COVID‐19

R. Franco, A. Rodriguez-Perez, J. Labandeira-Garcia, 2021, Clinical and translational medicine.

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

C. Labandeira, R. Yáñez Baña, M. G. Alonso Losada, 2022, Brain sciences.

AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

J. Lanciego, A. Rodriguez-Perez, J. Labandeira-Garcia, 2022, Brain, Behavior, and Immunity.

Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease

J. Labandeira-Garcia, C. Labandeira, A. Muñoz, 2020, British journal of pharmacology.

Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2021, Journal of Autoimmunity.

Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

I. Parees, J. Kulisevsky, P. Martínez-Martín, 2020, Scientific Reports.

Predictors of clinically significant quality of life impairment in Parkinson’s disease

I. Parees, J. Kulisevsky, P. Martínez-Martín, 2021, npj Parkinson's Disease.

Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort.

I. Parees, J. Kulisevsky, P. Martínez-Martín, 2019, Parkinsonism & related disorders.

The impact of freezing of gait on functional dependency in Parkinson’s disease with regard to motor phenotype

I. Parees, J. Kulisevsky, P. Martínez-Martín, 2020, Neurological Sciences.

Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA

J. Labandeira-Garcia, C. Labandeira, A. Muñoz, 2020, Frontiers in Neuroanatomy.

Interaction between brain angiotensin and dopaminergic systems and Parkinson's disease

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2020 .

Maintenance treatment in metastatic colorectal cancer: in search of the best strategy

R. Vera, C. Labandeira, A. Montes, 2020, Clinical and Translational Oncology.

COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

I. Parees, J. Kulisevsky, P. Martínez-Martín, 2019, European journal of neurology.

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

C. Labandeira, R. Yáñez Baña, M. G. Alonso Losada, 2021, Advances in Therapy.

Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2022, Frontiers in Medicine.

AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

J. Lanciego, A. Rodriguez-Perez, J. Labandeira-Garcia, 2022, Brain, Behavior, and Immunity.

ANGIOTENSIN TYPE-1 RECEPTOR AND ACE2 AUTOANTIBODIES IN PARKINSON´S DISEASE

J. Labandeira-Garcia, C. Labandeira, P. Garrido-Gil, 2023, IBRO Neuroscience Reports.

Cognitive impairment and dementia in young onset Parkinson’s disease

I. Parees, E. Erro, A. Horta-Barba, 2023, Journal of Neurology.

Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

A. Rodriguez-Perez, J. Labandeira-Garcia, C. Labandeira, 2023, Antioxidants.

The role of the brain renin-angiotensin system in Parkinson´s disease

A. Rodriguez-Perez, C. Labandeira, M. Guerra, 2024, Translational neurodegeneration.